GSK plc (NYSE:GSK) is included among the 15 Global Dividend Stocks to Diversify Your Portfolio.

On December 10, HSBC analyst Rajesh Kumar raised his company price target on GSK plc (NYSE:GSK) to GBp 1,500 from GBp 1,200 and maintained a reduce rating on the stock. The move came as part of HSBC’s 2026 outlook for the pharmaceutical sector. The company said the group is positioned to outperform next year, “even more so if the AI ​​panic kicks in.”

HSBC added that its preferred names are in the “ideas of the growth bucket”, although it noted that “fallen angels and equity could also work”.

A few days later, on December 16, GSK plc (NYSE:GSK) shared an update on the regulatory front. The US Food and Drug Administration approved the company’s add-on treatment for severe asthma, giving patients access to a therapy that requires less frequent dosing. At the same time, the agency refused to approve the drug for another condition.

The decision comes as GSK prepares for a leadership transition. Commercial chief Luke Miels will take over as CEO early next year as the company grapples with US tariffs and looks to replenish its portfolio as key patents near expiry.

The FDA cleared Exdensur as additional maintenance treatment for patients 12 years of age and older with severe eosinophilic asthma. The approval makes it the first biologic available with a biannual dosing schedule. GSK said the agency did not approve the drug for the treatment of chronic rhinosinusitis with nasal polyps, a long-term inflammatory disease of the sinuses.

In the UK, regulators had already approved the drug, under the brand name Exdensur, for use as an add-on treatment for asthma in patients aged 12 and over. UK authorities also cleared it for chronic rhinosinusitis with nasal polyps in adults, a broader label than the one granted by the FDA.

GSK plc (NYSE:GSK) operates as a global biopharmaceutical company focused on drug and vaccine development, with core strengths in respiratory disease, immunology and infectious disease.

While we recognize GSK’s potential as an investment, we believe some AI stocks offer greater upside potential and less downside risk. If you’re looking for an extremely undervalued AI stock that will also benefit significantly from Trump-era tariffs and the onshoring trend, check out our free report on the best short term AI stock.

READ THE FOLLOWING: 13 Highest Paying Monthly Dividend Stocks to Buy i 15 dividend stocks with low payout ratios and strong upside

Disclosure: no.